

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450 on November 28, 2006.

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney



1Fu/1632
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1632
Patent Application
Docket No. USF-183XC1
Serial No. 10/526,584

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)
Art Unit : 1632
Applicant : Shyam S. Mohapatra
Serial No. : 10/526,584
Filed : March 3, 2005
For : Materials and Methods for Treatment of Allergic Diseases

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, the applicant has not submitted copies of the U.S. patent or published U.S. application cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. §1.98(a)(2)(ii).

The applicant respectfully asserts that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Glenn P. Ladwig

Glenn P. Ladwig
Patent Attorney

Registration No. 46,853
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (4 pages); copies of some references cited therein



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/526,584
				Filing Date	March 3, 2005
				First Named Inventor	Shyam S. Mohapatra
				Art Unit	1632
				Examiner Name	
Sheet	1	of	4	Attorney Docket Number	USF-183XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2002/0146821 A1	10-10-2002	Sanchez-Ramos et al.	All
	U2	US-6,528,245 B2	03-04-2003	Sanchez-Ramos et al.	All
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			
	U	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ - Kind Code ⁵ (if known)			
	F1	WO	00/71576 A2	11-30-2000	Mayo Foundation	All
	F					
	F					
	F					
	F					
	F					
	F					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/526,584	
			Filing Date	March 3, 2005	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1632	
			Examiner Name		
Sheet	2	of	4	Attorney Docket Number	USF-183XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	CHEN, X. <i>et al.</i> "Human bone marrow stromal cell cultures" <i>J Neurosci Res</i> , 2002, 69:687-691.	
	R2	CHEN, X. <i>et al.</i> "Ischemic rat brain extracts induce human marrow stromal cell growth factor production" <i>Neuropathology</i> , 2002, 22:275-279.	
	R3	CHEN, J. <i>et al.</i> "Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats" <i>Stroke</i> , 2001, 32:1005-1011.	
	R4	CHEN, J. <i>et al.</i> "Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats" <i>J. Neurological Sci.</i> , 2001, 189:49-57.	
	R5	CHOPP, M. <i>et al.</i> "Spinal cord injury in rat: treatment with bone marrow stromal cell transplantation" <i>Neuroreport</i> , 2000, 11:3001-3005.	
	R6	DOCZI, T.P. <i>et al.</i> "Atrial natriuretic peptide (ANP) attenuates brain oedema accompanying experimental subarachnoid haemorrhage" <i>Acta Neurochir (Wien)</i> , 1995, 132:87-91.	
	R7	JENSEN, K.T. <i>et al.</i> "A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases" <i>Scand J Clin Lab Invest</i> , 1997, 57:529-540.	
	R8	KANEKO, T. <i>et al.</i> "C-type natriuretic peptide (CNP) is the major natriuretic peptide in human cerebrospinal fluid" <i>Brain Res</i> , 1993, 612:104-109.	
	R9	KOJIMA, M. <i>et al.</i> "Cloning and sequence analysis of cDNA encoding a precursor for rat brain natriuretic peptide" <i>Biochem. Biophys. Res. Commun.</i> , 1989, 159(3):1420-1426.	
	R10	LI, Y. <i>et al.</i> "Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice" <i>Journal of Cerebral Blood Flow & Metabolism</i> , 2000, 20:1311-1319.	
	R11	LI, Y. <i>et al.</i> "Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery" <i>Neurology</i> , 2002, 59:514-523.	
	R12	LU, D. <i>et al.</i> "Adult bone marrow stromal cells administered intravenously to rats after traumatic brain injury migrate into brain and improve neurological outcome" <i>Neuroreport</i> , 2001, 12:559-563.	
	R13	MAHMOOD, A. <i>et al.</i> "Treatment of traumatic brain injury in female rats with intravenous administration of bone marrow stromal cells" <i>Neurosurgery</i> , 2001, 49:1196-1204.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/526,584	
			Filing Date	March 3, 2005	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1632	
			Examiner Name		
Sheet	3	of	4	Attorney Docket Number	USF-183XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	MAHMOOD, A. <i>et al.</i> "Intracranial bone marrow transplantation after traumatic brain injury improving functional outcome in adult rats" <i>Journal of Neurosurgery</i> , 2001, 94:589-595.	
	R15	MAHMOOD, A. <i>et al.</i> "Intracerebral transplantation of marrow stromal cells cultured with neurotrophic factors promotes functional recovery in adult rats subjected to traumatic brain injury" <i>J Neurotrauma</i> , 2002, 19:1609-1617.	
	R16	NAKAO, N. <i>et al.</i> "Effect of atrial natriuretic peptide on ischemic brain edema: Changes in brain water and electrolytes" <i>Neurosurgery</i> , 1990, 27:39-44.	
	R17	NARUSE, S. <i>et al.</i> "Effects of atrial natriuretic peptide on brain oedema: The change of water, sodium, and potassium contents in the brain" <i>Acta Neurochir Suppl (Wien)</i> , 1990, 51:118-121.	
	R18	NOCERA, R. <i>et al.</i> "Novel strategies of neuroprotection against pathologic consequences of stroke in the aged brain" <i>Society for Neurosci. Abstracts</i> , 2001, 27(2):2302, Meeting date November 10-15, 2001.	
	R19	OGAWA, Y. <i>et al.</i> "Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene" <i>J. Clin. Invest.</i> , 1994, 93(5):1911-1921.	
	R20	PORTER, J.G. <i>et al.</i> "Cloning of a cDNA encoding porcine brain natriuretic peptide" <i>J. Biol. Chem.</i> , 1989, 264(12):6689-6692.	
	R21	QUAN, H. <i>et al.</i> "Inducible regulation of human brain natriuretic peptide promoter in transgenic mice" <i>Am. J. Physiol. Heart Circ. Physiol.</i> , 2001, 280:H368-H376.	
	R22	ROY, R.N. and FLYNN, T.G. "Organization of the gene for iso-rANP, a rat B-type natriuretic peptide" <i>Biochem. Biophys. Res. Commun.</i> , 1990, 171(1):416-423.	
	R23	SANCHEZ-RAMOS, J.R. "Neural cells derived from adult bone marrow and umbilical cord blood" <i>J. Neurosci. Res.</i> , 2002, 69:880-893.	
	R24	SEILHAMER, J.J. <i>et al.</i> "Human and canine gene homologs of porcine brain natriuretic peptide" <i>Biochem. Biophys. Res. Commun.</i> , 1989, 165(2):650-658.	
	R25	SONG, S. <i>et al.</i> "Nerve growth factor and retinoic acid induce development of neuronal cells from bone marrow stromal cells of both young and old mice" <i>Society for Neurosci. Abstracts</i> , 2001, 27(1):940, Meeting date November 10-15, 2001.	
	R26	SONG, S. <i>et al.</i> "Expression of brain natriuretic peptide by human bone marrow stromal cells" <i>Society for Neurosci. Abstracts</i> , 2002, Abstract No. 824.3, Meeting date November 2-7, 2002.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

4

Application Number

10/526,584

Filing Date

March 3, 2005

First Named Inventor

Shyam S. Mohapatra

Group Art Unit

1632

Examiner Name

Attorney Docket Number

USF-183XC1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	SONG, S. and SANCHEZ-RAMOS, J. "Preparation of Neural Progenitors from Bone Marrow and Umbilical Cord Blood" in <i>Protocols for Neural Stem Cell Methods</i> , Zigova, T. <i>et al.</i> , Eds., 2002, pp.79-88.	
	R28	SONG, S. <i>et al.</i> "Expression of brain natriuretic peptide by human bone marrow stromal cells" <i>Experimental Neurology</i> , 2004, 185:191-197.	
	R29	STEINHELPER, M.E. "Structure, expression, and genomic mapping of the mouse natriuretic peptide type-B gene" <i>Circ. Res.</i> , 1993, 72(5):984-992.	
	R30	SUDOH, T. <i>et al.</i> "Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain" <i>Biochem Biophys Res Commun</i> , 1988, 155:726-732.	
	R31	VLASUK, G.P. <i>et al.</i> "Structure and analysis of the bovine atrial natriuretic peptide precursor gene" <i>Biochem. Biophys. Res. Commun.</i> , 1986, 136(1):396-403.	
	R32	ZIVIN, R.A. <i>et al.</i> "Molecular cloning and characterization of DNA sequences encoding rat and human atrial natriuretic factors" <i>Proc. Natl. Acad. Sci. USA</i> , 1984, 81(20):6325-6329.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.